GENE ONLINE|News &
Opinion
Blog

2026-02-11|

Shriners Children’s Launches Multi-Center Study on Fractional CO2 Laser Technology for Pediatric Burn Care

by GOAI
Share To

Shriners Children’s has initiated a multi-center study to explore the use of fractional CO2 laser technology in pediatric burn care. The study aims to establish new clinical standards for treating burn injuries and seeks to influence insurance coverage policies across the United States. This research effort involves multiple medical centers and focuses on evaluating the therapeutic benefits of fractional CO2 lasers, which are designed to improve outcomes for burn patients.

The study will examine how this advanced laser technology can be integrated into current treatment protocols for children with burn injuries. Researchers aim to assess its effectiveness in reducing scarring, improving skin elasticity, and enhancing overall recovery. By gathering data from various participating centers, Shriners Children’s intends to create evidence-based guidelines that could potentially reshape how burn care is delivered nationwide. Additionally, findings from the study may inform discussions with insurance providers about expanding coverage for innovative treatments like fractional CO2 laser therapy.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 12, 2026

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
LATEST
AECOM Consortium Selected for Initial Phase of £200 Million STEP Fusion Energy Program
2026-03-17
Garmin Smartwatches Now Support WhatsApp Messaging and Notifications
2026-03-17
Fractyl Health to Release 2025 Financial Results and Business Updates on March 24, 2026
2026-03-17
EXL Service Holdings Announces $125 Million Accelerated Share Repurchase Program
2026-03-17
Yukon Metals Files Technical Report for AZ Project in Yukon on March 17, 2026
2026-03-17
Sono-Tek and Diamond Quanta Collaborate on Ultrasonic Coating for Engineered Diamond Applications
2026-03-17
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data for Highest Dose Cohort in Eosinophilic Esophagitis Trial
2026-03-17
Scroll to Top